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Europe approximated fraction of HPV-driven oropharyngeal 
cancers is 25%, and laryngeal cancers only 5%, versus 50% and 
35% suggested by HPV DNA studies for these anatomical sites, 
respectively. The use/usefulness of specific markers and 
marker combinations to define an HPV-driven tumor will be 
discussed. 
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The recent understanding of mechanisms of HPV-induced 
carcinogenesis has lead to the development of prophylactic 
vaccines, however radiotherapy still remains a major therapy 
in HPV-related cancer and despite concurrent chemotherapy, 
the outcome remains suboptimal. Therefore, improving the 
radiotherapeutic index remains an important challenge as 
well as defining predictive assays for treatment outcome of 
HPV-related tumours. Elucidating the influence of the HPV 
virus on tumour radiosensitivity is of major interest. There is 
several lines of evidence showing that head and neck HPV-
positive tumours have better outcome compared to non HPV 
related tumours and given the role of HPV oncoproteins on 
tumor immunity, it is possible that the feature of immune 
and microenvironmental factors during radiation response 
could be specific to HPV related tumors. Genetic feature of 
HPV+ cervical cancer has also been investigated and 3q gain 
has been shown to be particularly frequent in cervical 
cancers infected with the HPV16 virus type (84%) as well as in 
oropharyngeal and lung cancers. Other cancers such as anal 
and penile cancers are caused by or at least are associated 
with HPV infection. HPV-associated malignancies have 
common molecular feature, however specific response can 
also be expected and interfere with response to radiotherapy 
such as the contribution of organ-specific microbiota. In any 
case, investigating radiation response in this various type of 
cancer would help to decipher the role of HPV in radiation 
sensitivity and assess whether HPV+ cancer cells are 
intrinsically more sensitive to radiotherapy; or if HPV+ 
tumors release upon radiotherapy immunogenic viral proteins 
that promote tumor clearance and may prevent 
recurrence.This difference may allow for different 
combination of treatment strategies to be developed.  
   
SP-0491   
Clinical data (H&N, cervix, vulva, anal) 
P. Lassen1 
1Aarhus University Hospital, Department of Experimental 
Clinical Oncology, Aarhus C, Denmark   
  
Approximately 5% of all cancers worldwide are considered 
attributable to Human papillomavirus (HPV) and as such HPV 
associated cancers constitute a significant global disease 
burden. A causal relationship between HPV and cervical 
cancer was established almost 40 years ago and HPV is 
necessary for the development of cervical cancers, of which 
more than 99% harbour virus. Detection rates of HPV at other 
ano-genital sites (vulva, vagina and anus) are somewhat 
lower (65-80%), and clinical data suggest that outcome at 
these sites differ significantly dependent on the HPV-status 
of the tumors, in a way that patients with HPV-positive 
tumors have better prognosis compared to HPV-negative 
patients. 
In head and neck cancer (HNSCC), tobacco and alcohol were 
until recently considered to be the major risk factors for 
carcinogenesis. However, the putative role of HPV in HNSCC 
has been investigated since the 1980s, and at present 
sufficient molecular and pathological evidence exists to 
etiologically link HPV to a subset of HNSCCs. The strongest 
association with HPV is found in oropharynx cancer (OPC) 
where tumors of the tonsils are particularly associated with 
HPV infection, but high-risk HPV, predominantly HPV-16, has 
been found in HNSCC from all sites although with a 
significantly higher prevalence in OPC compared to tumors 
arising outside the oropharyngeal region (non-OPC).  
Numerous clinical studies have demonstrated a highly 
significant impact of tumour HPV/p16-status on radiotherapy 
(RT) outcome in advanced OPC where the influence of tumor 
HPV/p16-status seems indisputable. These observations are 
believed to be caused in part by a higher sensitivity of 
HPV/p16-positive tumors to RT, combined with a different 
and more favourable risk factor profile (including less heavy 
tobacco history) and better general health status in the group 
of patients with HPV/p16-positive disease. Less is known 
about the influence of HPV/p16-status in non-OPC and 
clinical data published so far have reached different 
conclusions. Data based on a rather large cohort of patients 
with advanced larynx and hypopharynx cancer treated with 
primary (chemo)radiotherapy suggested that the prognostic 
impact of HPV/p16-status does not extend to tumors of non-
oropharyngeal origin. The reasons for this apparent site-
specific difference in the prognostic impact of HPV/p16-
status in HNSCC remain unsolved and warrant further 
investigation. 
Presently there is substantial variation in the treatment 
strategies considered for patients with head and neck cancer 
dependent of the HPV/p16-status of the tumors. Some 
clinical trials are investigating whether de-intensified 
treatment strategies could result in avoidance of excessive 
toxicity without compromising outcome for selected patients 
with “low-risk” HPV/p16-positive OPC. At the opposite end of 
the spectrum other trials are investigating whether additional 
intensification of treatment could be beneficial for patients 
with HPV/p16-negative HNSCC based on their observed poor 
outcome, in order to secure optimal and safe treatment for 
these patients also. 
   
OC-0492   
Estimation of HPV 16 and 18 subtypes, viral load and 
correlation with response to radio (chemo) therapy in 
cervical cancers 
U. Mahantshetty1, T. Teni2, C. Hotwani1, S.N. Sagar3, V. 
Hande1, R. Engineer1, S. Chopra2, S.K. Shrivastava1 
1Tata Memorial Hospital, Radiation Oncology, Mumbai, India  
2ACTREC TMC, Radiation Oncology, Navi Mumbai, India  
3ACTREC, Radiation Oncology, Navi Mumbai, India  
 
Purpose/Objective: Etiologic role of Human Papilloma Virus 
(HPV) in cervical cancer is well established. Radio (chemo) 
therapy remains the mainstay of treatment. Response, 
relapses & overall outcome and correlation with HPV is not 
well known. With an aim to study this we undertook this 
study. 
Materials and Methods: After Institutional Ethical clearance 
and obtaining written informed consent patients were invited 
to participate in this prospective observational study. 
Patients who were treated with radio (chemo) therapy for 
cervical cancer underwent quantitative estimation of HPV 16 
and 18 viral load pre treatment, at treatment completion, 2 
and 5 months post treatment on cervical biopsies/ brushings 
using polymerase chain reaction (PCR). The viral load were 
compiled, evaluated and correlated with standard clinical 
response evaluation. 
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Results: Out of 108 patients treated with radio (chemo) 
therapy, 76 patients had HPV 16 positivity, 24 HPV 16 & 18, 1 
patient HPV 18 while 6 patients were HPV 16 & 18 negative. 
The mean HPV 16 and HPV 18 viral load was 9.3x106 
copies/10ng DNA and 1.3x106 copies/10 ng DNA respectively. 
At 5 months post treatment, 96 patients had complete 
response, 9 had residual/ recurrent local disease and 3 had 
distant relapse. There was significant reduction in HPV viral 
load at treatment completion, 2 and 5 months post 
treatment in complete responders (p 
Conclusions: A significant reduction in HPV 16 and 18 viral 
load occurs in complete responders after completion of 
radical radio (chemo) therapy. However, further correlation 
between persistence or re-infection of HPV and local 
recurrence is ongoing in this prospective study.  
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Purpose/Objective: Head and neck squamous cell carcinoma 
(HNSCC) associated with HPV has improved response to 
radiation therapy compared to HPV non-associated SCC. 
However, despite this, examples of local failures within 
HNSCC are beginning to emerge. This work aims to 
understand and describe risk factors to radiation resistance 
and increased virulence. HPV-16 non-European (NE) variants 
have been shown to have an 11-fold increased association 
with cervical cancer diagnosis than the European (E) variants. 
Materials and Methods: Our initial analysis of 43 HPV-16 
positive human tumors with PCR that E variants were more 
likely associated with higher stage and lymph node positive 
disease. E2 sequencing was completed for a subset of HPV 16 
variants and analized. The presence of intact E2 DNA has 
shown improved local control and a trend for improved 
disease free survival, for head and neck cancer and cervical 
cancer respectively. To test this, we evaluated five head and 
neck SCC cell lines for presence of intact E2 DNA and mRNA 
using E2 PCR primers. Clonogenic survival assays were 
completed and colony formation was determined. 
Results: E variants were detected more often in higher stage 
HNSCC (79% stage IV v 57% stage I-III, p=0.160) and were also 
more prevalent in node positive disease (82% v 53%, p=0.074). 
Additional tumor HPV 16 variant sequencing needs to be 
completed to more statistical power to detect differences in 
virulence and presentation of malignancy. The subset of 
cancer tissue variant E2 sequencing revealed variation within 
areas know to bind p53 and may affect apoptosis. H&N 
cancer cell line E2 DNA and mRNA expression was confirmed 
and results reveal that E2 disrupted or absent cell lines were 
significantly more radioresistant than their counterparts.  
Conclusions: Preliminary evidence suggests that HPV 16 
variants may be a important factor in evaluation and risk 
stratification. In addition, E2 may serve as a useful tool to 
determine which patients harbor tumors that are 
radioresistant in HPV-positive HNSCC and has implications for 
tumor specific cancer treatments.  
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It is a general belief that patients with oliometastases 
benefit from local ablation of the metastases. Large 
retrospective cohort studies have shown favorable survival 
outcome after surgical resection and radiofrequency 
ablation. Stereotactic body radiation therapy (SBRT) is 
increasingly used for this purpose. Unfortunately, the 
evidence for the use of SBRT of metastases is limited to 
relatively small retrospective studies often with patients with 
various histological types. Colorectal carcinoma (CRC) 
metastasis are often treated with surgery and RFA and it is 
one of the indication where we have the best published 
experience with SBRT.  
A large cohort of CRC patients with metastases primarily in 
the lungs and liver treated with SBRT was published recently 
(1). This study demonstrated promising survival rates of 77, 
33 and 15% at 1, 3 and 5 years after SBRT in a cohort of 
patients who had already received other treatments for 
metastatic disease. Multivariate analysis revealed that WHO 
performance status (0-1) solitary metastasis and small size of 
metastasis (≤ 30 mm) were significantly related to favorable 
survival. The survival of metastatic CRC did not significantly 
differ from the survival of non-CRC metastases patients 
treated with SBRT and the analysis did not identify any tumor 
type with a more favorable outcome when metastases were 
treated with SBRT. 
In general, the approach to metastatic CRC has become more 
aggressive. A number of specialties offer therapies for 
patients with liver oligo-metastases and a multidisciplinary 
team approach in the management of these patients is highly 
important. SBRT may be utilized for a group of patients who 
cannot be treated with surgery. 
 There is sufficient data demonstration that SBRT can be used 
in therapy of CRC metastases, but there is a great need for 
randomized clinical trials to prove the efficacy of SBRT in 
treatment of oligo-metastases and for trials to explore the 
need for systemic therapy along with SBRT. 
Reference:  
1. Mette Marie Fode, Morten Høyer: Survival and 
prognostic factors in 321 patients treated with 
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metastases, Radiother Oncol In press 2015  
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